Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(3 sites)
Canada
Novartis Investigative Site, Ottawa, Ontario Montreal Neurological Institute, Montreal, Quebec CIUSS de l´Estrie-CHUS- Hôpital Fleurimont, Sherbrooke, Quebec